Cytopia's Ph I CYT997 achieves primary objectives

Australian biotechnology firm Cytopia says that it has successfully concluded dose-escalation in its Phase I intravenous trial for CYT997, its anticancer vascular-disrupting agent.

The primary objectives of this safety and tolerability study - determination of the maximum tolerated dose and dose-limiting toxicities when the compound was administered as a 24-hour IV infusion to patients with a diverse range of solid tumors on a three-weekly cycle - were met, the firm noted.

Cytopia is also conducting a second Phase III dose-escalation study of the agent as an oral capsule formulation. The this, which is partly funded under a A$3.0 million ($2.6 million) commercial ready grant, is being conducted at two locations in Queensland and is expected to conclude in December.